Shilpa Medicare rallied 10.46% to Rs 503 after the company said it has entered into a three-year definitive agreement with Dr. Reddy s Laboratories for production and supply of the Sputnik V vaccine.In an exchange filing on Monday, Shilpa Medicare said that through its wholly owned subsidiary, Shilpa Biologicals, will produce and supply the Sputnik V vaccine from its integrated biologics R&D cum manufacturing center at Dharwad, Karnataka.
The targeted production of the dual vector Sputnik V for the first 12 months is 50 million doses (50 million of Component 1 and 50 million of component 2), from the date of start of commercial production.
Dr. Reddy s has partnered with HV/RDIF for clinical development of the vaccine and has distribution rights in geographies including India. Dr. Reddy s will facilitate the transfer of the sputnik technology to Shilpa Biologicals. Under the agreement, Shilpa Biologicals will be responsible for manufacture of the vaccine, while DRL is responsible fo
Read more about Shilpa Medicare arm inks pact with Dr Reddy s to manufacture Sputnik V vax on Business Standard. Drug firm Shilpa Medicare on Monday said its arm has entered into a definitive agreement with Dr Reddy s Laboratories for manufacturing of Russian COVID-19 vaccine Sputnik V."The company, via its wholly owned subsidiary Shilpa Biologicals Pvt Ltd
For production of Sputnik V vaccineShilpa Medicare, via its wholly owned subsidiary, Shilpa Biologicals has entered into a 3 year definitive agreement with Dr Reddys Laboratories (DRL) for production-supply of Sputnik V vaccine from its integrated biologics R&D cum manufacturing center at Dharwad, Maharashtra.
The targeted production of the dual vector Sputnik V for the first 12 months is 50 million doses (50 million of Component 1 and 50 million of component 2), from the date of start of commercial production.
DRL has partnered with HVIRDIF for clinical development of the vaccine and has distribution rights in geographies including India. DRL will facilitate the transfer of the sputnik technology to SBPL. Under the agreement, SBPL will be responsible for manufacture of the vaccine, while
Shilpa Medicare arm inks pact with Dr Reddy s to manufacture Sputnik V vaccine
SECTIONS
Last Updated: May 17, 2021, 10:41 AM IST
Share
Synopsis The company, via its wholly owned subsidiary Shilpa Biologicals Pvt Ltd (SBPL), has entered into a three year definitive agreement with Dr Reddy s Laboratories for production-supply of the Sputnik V vaccine from its integrated biologics R&D cum manufacturing center at Dharwad, Karnataka, Shilpa Medicare said in a regulatory filing.
Reuters
Drug firm
Shilpa Medicare on Monday said its arm has entered into a definitive agreement with Dr Reddy s Laboratories for manufacturing of Russian COVID-19 vaccine Sputnik V. The company, via its wholly owned subsidiary Shilpa Biologicals Pvt Ltd (SBPL), has entered into a three year definitive agreement with Dr Reddy s Laboratories for production-supply of the Sputnik V vaccine from its integrated biologics R&D cum manufacturing center at Dharwad, Karnataka, Shilpa Medicare said in a regula
Shilpa Medicare unit inks pact with Dr Reddy s to manufacture Sputnik V vaccine yourstory.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yourstory.com Daily Mail and Mail on Sunday newspapers.